AdaptBio Therapeutics

AdaptBio is a biotechnology company dedicated to discovering and developing first-in-class therapies for neurodegenerative diseases. The company's core strategy revolves around its Adaptive Biology platform, which targets the mechanisms cells use to respond to stress and maintain protein homeostasis. By focusing on the regulation of TDP-43 and other key proteins associated with neurodegeneration, AdaptBio aims to provide disease-modifying treatments for conditions like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Incubated by Apple Tree Partners (ATP), the company combines deep expertise in neuroscience with a novel approach to cellular resilience. The firm is currently advancing its lead programs through pre-clinical development to address significant unmet needs in the neurology space.